Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.15, read 2026-10-23
Ethical does not pass the values gate
Price35.67 USD
Fair value71.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown39.28-9.2% to today ✓Accumulation gives way to Markdown after a 59% rise in 13 weeks
2026-07-02Read Accumulation24.75+44.1% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Definium Therapeutics, Inc. holds its Markdown at $35.67. Consolidating, no directional conviction, held for 49 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 49 days
Price at the screen
$35.67
Valuation
N/A trailing · -18.55 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.19
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
9.22%
Below 33%
Interest-bearing debt is just 9.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
34.94%
Below 33%
Interest-bearing cash and securities are 34.9% of assets, above the one-third limit.
Fail
Receivables
58.59%
Below 49%
Money owed to the company is 58.6% of assets, above the 49% limit.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Definium Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 35% of its assets, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DFTX's ethical verdict changes
Today DFTX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 97.2% margin of safety to the base estimate.
Third-party analyst targets: 18 covering, consensus Strong Buy. The average target sits +99% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech Pipeline Lacks Any Usable Numbers
A firm chasing phase-three drugs for anxiety and depression sounds like a breakthrough story until you check the books. Definium shows zero profit margin, negative ninety-five percent return on equity and a forward price-to-earnings ratio that is deeply negative. With no financial ratios available the ethical screen returns insufficient data and the opportunity rating sits at none, so we pass.
The analyst crowd still calls it a strong buy with a fifty-seven dollar median target against the current forty-four dollar price. That gap looks tempting on paper yet the business burns cash with an unknown moat and no earnings to anchor any valuation. Markets reward clinical progress but they punish missing numbers first.
Risk sits in the total lack of visibility on cash burn, dilution and eventual profitability, all standard red flags in early-stage biotech. One failed trial or extra funding round could wipe out the apparent margin of safety quickly. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DFTX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markdown$36.00+5.1%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 38% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 194%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (15 analysts) rates it strong buy, with a mean price target of $39.
2026-10-21Markdown$34.26-7.2%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 36% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 194%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (15 analysts) rates it strong buy, with a mean price target of $39.
2026-10-14Markdown$36.90-6.1%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 54% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 194%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (15 analysts) rates it strong buy, with a mean price target of $39.
2026-10-02Markdown · changed$39.28-8.2%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 54% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 194%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (15 analysts) rates it strong buy, with a mean price target of $39.
2026-08-26Accumulation$42.79-3.4%Entry 5
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 54% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 194%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (15 analysts) rates it strong buy, with a mean price target of $39.
2026-07-26Accumulation$44.29+78.9%Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 78.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 54% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 194%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (15 analysts) rates it strong buy, with a mean price target of $39.
2026-07-18Accumulation$24.75+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 54% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 194%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (15 analysts) rates it strong buy, with a mean price target of $39.
2026-07-03Accumulation$24.75+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$24.75Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.